Table 1.
Sample Characteristics, Frequencies, and Associations with Social Information Needs
| |
Talk about cancer with family and friends (TAC) |
Meet peer survivors (MPS) |
||||
|---|---|---|---|---|---|---|
| |
n=477 |
n=462 |
||||
| No information need n (Row %) | Information need n (Row %) | p | No information need n (Row %) | Information need n (Row %) | p | |
| Total | 359 (75.3) | 118 (24.7) | 263 (56.9) | 199 (43.1%) | ||
| Sociodemographics | ||||||
| Age at diagnosis | ||||||
| 15–19 | 55 (88.7) | 7 (11.3) | 45 (73.8) | 16 (26.2) | ||
| 20–29 | 154 (74.4) | 53 (25.6) | 111 (54.4) | 93 (45.6) | ||
| 30–39 | 150 (72.1) | 58 (27.9) | 0.03 | 107 (54.3) | 90 (45.7) | 0.02 |
| Gender | ||||||
| Male | 226 (75.3) | 74 (24.7) | 165 (57.3) | 123 (42.7) | ||
| Female | 133 (75.1) | 44 (24.9) | 0.96 | 98 (56.3) | 76 (43.7) | 0.84 |
| Race/ethnicity | ||||||
| Non-Hispanic white | 248 (80.8) | 59 (19.2) | 181 (60.9) | 116 (39.1) | ||
| Non-Hispanic black | 24 (64.9) | 13 (35.1) | 18 (46.2) | 21 (53.8) | ||
| Hispanic | 52 (63.4) | 30 (36.6) | 38 (48.7) | 40 (51.3) | ||
| Other/unknown | 35 (68.6) | 16 (31.4) | 0.002 | 26 (54.2) | 22 (45.8) | 0.11 |
| Education | ||||||
| High school grad or less | 96 (73.3) | 35 (26.7) | 77 (61.1) | 49 (38.9) | ||
| Some college/associate degree | 125 (72.3) | 48 (27.7) | 88 (52.4) | 80 (47.6) | ||
| College grad or more | 137 (79.7) | 35 (20.3) | 0.24 | 97 (58.1) | 70 (41.9) | 0.30 |
| Missinga | 1 | 0 | 1 | 0 | ||
| Health insurance status at diagnosis | ||||||
| Uninsured | 46 (70.8) | 19 (29.2) | 38 (56.7) | 29 (43.3) | ||
| Insured | 307 (76.0) | 97 (24.0) | 0.37 | 221 (57.1) | 166 (42.9) | 0.95 |
| Missinga | 6 | 2 | 4 | 4 | ||
| Clinical/health variables | ||||||
| Cancer site | ||||||
| Hodgkin lymphoma | 96 (73.3) | 35 (26.7) | 75 (58.6) | 53 (41.4) | ||
| NHL | 84 (71.2) | 34 (28.8) | 57 (48.7) | 60 (51.3) | ||
| Germ cell | 143 (76.9) | 43 (23.1) | 107 (61.5) | 67 (38.5) | ||
| ALL | 18 (94.7) | 1 (5.3) | 11 (57.9) | 8 (42.1) | ||
| Sarcomab | 18 (78.3) | 5 (21.7) | 0.23 | 13 (54.2) | 11 (45.8) | 0.30 |
| Stage at diagnosis | ||||||
| Stage I | 147 (77.4) | 43 (22.6) | 110 (61.5) | 69 (38.5) | ||
| Stage II | 91 (76.5) | 28 (23.5) | 69 (59.5) | 47 (40.5) | ||
| Stage III | 41 (63.1) | 24 (36.9) | 29 (46.8) | 33 (53.2) | ||
| Stage IV | 42 (73.7) | 15 (26.3) | 31 (51.7) | 29 (48.3) | ||
| N/A (includes all ALL cases) | 23 (88.5) | 3 (11.5) | 14 (56.0) | 11 (44.0) | ||
| Unknown | 15 (75.0) | 5 (25.0) | 0.14 | 10 (50.0) | 10 (50.0) | 0.36 |
| Treatment | ||||||
| Surgery only | 45 (80.4) | 11 (19.6) | 32 (60.4) | 21 (39.6) | ||
| Radiation (w/ or w/o surgery) | 42 (85.7) | 7 (14.3) | 32 (72.7) | 12 (27.3) | ||
| Chemotherapy (w/ or w/o surgery) | 172 (76.8) | 52 (23.2) | 126 (56.8) | 96 (43.2) | ||
| Radiation and chemo (w/ or w/o surgery) | 78 (70.3) | 33 (29.7) | 57 (51.8) | 53 (48.2) | ||
| None or unknown | 22 (59.5) | 15 (40.5) | 0.03 | 16 (48.5) | 17 (51.5) | 0.14 |
| General health status | ||||||
| Excellent/very good | 174 (82.5) | 37 (17.5) | 133 (64.9) | 72 (35.1) | ||
| Good | 134 (73.6) | 48 (26.4) | 97 (54.8) | 80 (45.2) | ||
| Fair/poor | 48 (60.0) | 32 (40.0) | 0.0003 | 32 (41.6) | 45 (58.4) | 0.0015 |
| Missinga | 3 | 1 | 1 | 2 | ||
| Quality of care | ||||||
| Excellent/very good | 304 (78.4) | 84 (21.6) | 222 (59.4) | 152 (40.6) | ||
| Good | 41 (66.1) | 21 (33.9) | 31 (50.0) | 31 (50.0) | ||
| Fair/poor | 6 (35.3) | 11 (64.7) | <0.0001 | 5 (33.3) | 10 (66.7) | 0.06 |
| Missinga | 8 | 2 | 5 | 6 | ||
| Symptoms | ||||||
| 0–1 | 135 (85.4) | 23 (14.6) | 105 (67.7) | 50 (32.3) | ||
| 2–3 | 100 (78.7) | 27 (21.3) | 71 (58.2) | 51 (41.8) | ||
| 4+ | 124 (64.6) | 68 (35.4) | <0.0001 | 87 (47.0) | 98 (53.0) | 0.001 |
| Comorbidities | ||||||
| 0 | 247 (78.9) | 66 (21.1) | 185 (60.7) | 120 (39.3) | ||
| 1 | 61 (78.2) | 17 (21.8) | 40 (52.6) | 36 (47.4) | ||
| 2+ | 33 (58.9) | 23 (41.1) | 0.005 | 23 (43.4) | 30 (56.6) | 0.04 |
| Missinga | 18 | 12 | 15 | 13 | ||
| Support group services | ||||||
| Received | 29 (76.3) | 9 (23.7) | 21 (56.8) | 16 (43.2) | ||
| Not received/not needed | 296 (80.0) | 74 (20.0) | 236 (66.3) | 120 (33.7) | ||
| Not received/needed | 34 (49.3) | 35 (50.7) | <0.0001 | 6 (8.7) | 63 (91.3) | <0.0001 |
Note. p values<0.05 are indicated in bold.
a
Chi-square compares non-missing categories only.
b
Sarcoma types included Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.
ALL, acute lymphoblastic leukemia; N/A, non-applicable; NHL, non-Hodgkin lymphoma; w/, with; w/o, without.